IJC metabolic & endocrine最新文献

{"title":"Circulating eicosapentaenoic acid to oleic acid ratio and risk for cardiovascular events in patients with coronary artery disease: A sub-analysis of the SHINANO registry","authors":"Hirofumi Hioki,&nbsp;Takashi Miura,&nbsp;Yusuke Miyashita,&nbsp;Souichirou Ebisawa,&nbsp;Hirohiko Motoki,&nbsp;Atsushi Izawa,&nbsp;Jun Koyama,&nbsp;Uichi Ikeda,&nbsp;on behalf of the SHINANO registry investigators","doi":"10.1016/j.ijcme.2015.11.001","DOIUrl":"10.1016/j.ijcme.2015.11.001","url":null,"abstract":"<div><h3>Background</h3><p>The omega-3/omega-6 polyunsaturated fatty acid (PUFA) ratio, particularly the eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio, is associated with cardiovascular disease. However, the clinical impact of omega-9 monounsaturated fatty acids (MUFAs) on cardiovascular disease is not well understood. In this study, we evaluated whether the PUFA/MUFA ratio, especially the EPA/oleic acid (OA) ratio, predicted clinical outcomes in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI).</p></div><div><h3>Methods</h3><p>The SHINANO registry was a prospective, observational, multicenter cohort study that enrolled 1923 consecutive patients with CAD. From this registry, we identified 182 patients for whom fatty acids were measured on admission and stratified them according to the median EPA/OA ratio. The primary endpoint was major adverse cardiovascular events (MACEs), including cardiovascular death, nonfatal myocardial infarction, ischemic stroke, heart failure, and PCI for a de novo lesion within 1<!--> <!-->year.</p></div><div><h3>Results</h3><p>Patients' mean age was 72<!--> <!-->±<!--> <!-->9<!--> <!-->years, 24% were women, and 28% had acute coronary syndrome. The 1-year follow-up was completed in 181 patients (99.5%). There were 59 cases of MACE. In the Kaplan–Meier analysis, the MACE incidence was significantly higher in patients with an EPA/OA ratio of ≤<!--> <!-->0.1169 than in those with a ratio of ≥<!--> <!-->0.1170 (39.6% vs. 25.3%, p<!--> <!-->=<!--> <!-->0.041). In a multivariate Cox regression analysis, an EPA/OA ratio ≥<!--> <!-->0.1170 was associated with a lower incidence of MACE (hazard ratio, 0.53; 95% confidence interval, 0.31–0.91; p<!--> <!-->=<!--> <!-->0.020).</p></div><div><h3>Conclusions</h3><p>We demonstrated that the EPA/OA ratio predicted MACE in patients with CAD who underwent PCI.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"10 ","pages":"Pages 1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90716845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The response of NT-proBNP to intensified medication in advanced chronic heart failure","authors":"Hiroki Nakano ,&nbsp;Koichi Fuse ,&nbsp;Minoru Takahashi ,&nbsp;Sho Yuasa ,&nbsp;Tomoyasu Koshikawa ,&nbsp;Masahito Sato ,&nbsp;Masaaki Okabe ,&nbsp;Akira Yamashina ,&nbsp;Yoshifusa Aizawa","doi":"10.1016/j.ijcme.2016.01.001","DOIUrl":"10.1016/j.ijcme.2016.01.001","url":null,"abstract":"<div><h3>Background</h3><p>The clinical significance of excessively high serum NT-proBNP is poorly understood in chronic heart failure (HF).</p></div><div><h3>Methods</h3><p>One-hundred eighteen patients with advanced chronic HF (NYHA functional class III or IV) were admitted; of these patients, 42.4% exhibited NT-proBNP levels &gt;<!--> <!-->10,000<!--> <!-->pg/ml. The patients were divided into three groups as follows: ≥<!--> <!-->400 and &lt;<!--> <!-->10,000<!--> <!-->pg/ml, group I (n<!--> <!-->=<!--> <!-->68); ≥<!--> <!-->10,000 and &lt;<!--> <!-->20,000<!--> <!-->pg/ml, group II (n<!--> <!-->=<!--> <!-->28); and ≥<!--> <!-->20,000<!--> <!-->pg/ml, group III (n<!--> <!-->=<!--> <!-->22). The determinants of elevated NT-proBNP levels and responsiveness to HF medications were compared among these groups. A subgroup of HF patients with normal serum creatinine was analyzed separately.</p></div><div><h3>Results</h3><p>Overall, cardiac, renal and laboratory parameters (serum creatinine, potassium and uric acid, positively; and eGFR and hemoglobin, negatively) correlated with serum NT-proBNP levels. In patients with normal serum creatinine, left ventricular ejection fraction, serum potassium and hemoglobin correlated with serum NT-proBNP levels. In-hospital mortality was higher in patients with the highest NT-proBNP levels. After successful HF treatment, the patients in each group lost body weight and improved to NYHA class I or II, and NT-proBNP levels were halved, irrespective of their baseline levels. Excessively high NT-proBNP levels were related to cardiac, renal and laboratory abnormalities; therefore, the role and underlying mechanism of high NT-proBNP levels must be studied further.</p></div><div><h3>Conclusion</h3><p>Excessively high NT-proBNP levels in HF patients correlated with cardiac, renal and laboratory parameters. After successful HF treatment, NT-proBNP levels were halved, irrespective of their baseline levels. The precise role and underlying mechanism of NT-proBNP warrant further study.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"10 ","pages":"Pages 24-29"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2016.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83800887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunological markers of frailty predict outcomes beyond current risk scores in aortic stenosis following transcatheter aortic valve replacement: Role of neopterin and tryptophan","authors":"Adam Csordas ,&nbsp;Dietmar Fuchs ,&nbsp;Antonio H. Frangieh ,&nbsp;Gilbert Reibnegger ,&nbsp;Barbara E. Stähli ,&nbsp;Martin Cahenzly ,&nbsp;Fabian Nietlispach ,&nbsp;Willibald Maier ,&nbsp;Francesco Maisano ,&nbsp;Ronald K. Binder ,&nbsp;Christoph Liebetrau ,&nbsp;Won-Keun Kim ,&nbsp;Helge Möllmann ,&nbsp;Christian Hamm ,&nbsp;Thomas F. Lüscher","doi":"10.1016/j.ijcme.2015.11.002","DOIUrl":"10.1016/j.ijcme.2015.11.002","url":null,"abstract":"<div><h3>Background</h3><p>Frailty and associated comorbidities are often prohibitive surgical risk factors in symptomatic severe aortic stenosis. Transcatheter aortic valve replacement (TAVR) is a viable treatment option for such patients. However, biomarkers providing a precise estimate of individual vulnerability and hence pre-interventional risk for mortality are not available in this heterogenous patient population. Neopterin, a pteridine synthesized by activated macrophages, has been associated with prevalent frailty in elderly patients. Moreover, immune activation-mediated tryptophan degradation has been suggested to reflect frailty and reduced life expectancy in diverse chronic disease states.</p></div><div><h3>Methods</h3><p>We thus prospectively investigated a total of 185 patients undergoing TAVR and measured neopterin, kynurenine, tryptophan, tyrosine and phenylalanine levels at baseline and at day 1–3 post intervention. Royston-Parmar proportional hazards models were employed relating biomarkers to all-cause mortality.</p></div><div><h3>Results</h3><p>In bivariate analysis adjusted for EuroSCORE II, belonging to the upper quartile of neopterin (HR 5.7, 95% CI: 2.0–16.5, P<!--> <!-->&lt;<!--> <!-->0.01), KTR (HR 3.1, 95% CI: 1.1–8.5, P<!--> <!-->=<!--> <!-->0.02) and Phe/Tyr ratio (HR 2.8, 95% CI: 1.0–7.7, P<!--> <!-->=<!--> <!-->0.03) emerged as independent predictors of mortality. A similar finding on neopterin and KTR was obtained in 207 patients of an independent external validation cohort.</p></div><div><h3>Conclusions</h3><p>Increased immune activation and associated tryptophan degradation serve as hallmarks of frailty underscoring the prognostic role of baseline inflammation for outcome in patients with severe aortic stenosis undergoing TAVR, and thus may provide a future therapeuthic target in this elderly patient population.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"10 ","pages":"Pages 7-15"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.11.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82286999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate release niacin effect at stratified lipid levels","authors":"Elise Vo ,&nbsp;Stanley J. Goldberg","doi":"10.1016/j.ijcme.2015.10.004","DOIUrl":"10.1016/j.ijcme.2015.10.004","url":null,"abstract":"<div><h3>Background</h3><p>The Coronary Drug Project demonstrated a significant decrease in non-fatal myocardial infarction, and total mortality using immediate release niacin (IRN). However, AIM-HIGH and HPS-2-THRIVE showed no additional benefit from adding niacin to statin therapy.</p><p>Objective</p><p>To evaluate the efficacy and tolerability of IRN on low-density-lipoprotein-cholesterol (LDL-C), high-density-lipoprotein-cholesterol (HDL-C), triglycerides, and lipoprotein (a) (Lpa) at stratified lipid levels in a monotherapy IRN group (MTG) and a combined therapy group (CTG) statin<!--> <!-->+<!--> <!-->IRN.</p></div><div><h3>Methods</h3><p>We retrospectively studied 185 patients who were prescribed IRN for elevated LDL-C, triglycerides, lipoprotein a (Lpa), or low HDL-C. All patients used the same IRN products.</p></div><div><h3>Results</h3><p>157 patients had complete records. (MTG<!--> <!-->=<!--> <!-->74 patients, CTG<!--> <!-->=<!--> <!-->83 patients with 68 combined with statins). Mean IRN dose<!--> <!-->=<!--> <!-->2474<!--> <!-->mg. Mean duration<!--> <!-->=<!--> <!-->3.05<!--> <!-->years.</p><p>If initial LDL-C was &lt;<!--> <!-->130, LDL-C did not decrease significantly with IRN. If initial LDL-C<!--> <!-->&gt;<!--> <!-->=<!--> <!-->130, LDL-C decreased 35% in MTG vs. 32% decrease in CTG. If initial HDL-C<!--> <!-->&lt;<!--> <!-->40, there was a 40% increase in MTG vs. 61% increase in CTG. If initial triglycerides<!--> <!-->&gt;<!--> <!-->150, there was a 48% decrease in MTG vs. 54% decrease in CTG. Lpa decreased 49% for all patients with initially elevated Lpa. Data except for LDL-C<!--> <!-->&lt;<!--> <!-->130 were significant (p<!--> <!-->&lt;<!--> <!-->.001).</p></div><div><h3>Conclusion</h3><p>Lowering LDL-C is the corner stone for decreasing cardiovascular events. IRN reduces LDL-C significantly when initial LDL-C<!--> <!-->&gt;<!--> <!-->130, but not significantly when LDL-C<!--> <!-->&lt;<!--> <!-->130. Patients in AIM-HIGH and HPS-2-THIRVE received statin therapy causing very low initial LDL-C. Our results may explain why adding niacin to statin therapy failed in AIM-HIGH and HPS-2-THRIVE since niacin did not further lower LDL-C.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"9 ","pages":"Pages 48-53"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.10.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85087475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erectile dysfunction and cardiovascular disease","authors":"Shou-Guo Zhao ,&nbsp;Ji-Min Wang ,&nbsp;Rui-Jie Gao ,&nbsp;Tai Li ,&nbsp;Heng-Chen Yao","doi":"10.1016/j.ijcme.2015.08.001","DOIUrl":"https://doi.org/10.1016/j.ijcme.2015.08.001","url":null,"abstract":"","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"9 ","pages":"Pages 10-11"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137080093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired heart rate variability in patients with non-diabetic chronic kidney disease — Prominent disruption of vagal control and daily fluctuation","authors":"Hisaki Makimoto ,&nbsp;Katsuhito Fujiu ,&nbsp;Kohei Shimizu ,&nbsp;Tina Lin ,&nbsp;Eisuke Amiya ,&nbsp;Kazuo Asada ,&nbsp;Toshiya Kojima ,&nbsp;Masao Daimon ,&nbsp;Christian Meyer ,&nbsp;Issei Komuro","doi":"10.1016/j.ijcme.2015.10.003","DOIUrl":"10.1016/j.ijcme.2015.10.003","url":null,"abstract":"<div><h3>Background</h3><p>The circadian autonomic fluctuation in chronic kidney disease (CKD) patients has not yet been fully elucidated. The aim of this study was to compare the autonomic fluctuation using heart rate variability between patients with and without CKD.</p></div><div><h3>Methods</h3><p>The study population consisted of consecutive 101 non-diabetic CKD patients (Stages 3–5, 54 males, 70<!--> <!-->±<!--> <!-->10<!--> <!-->years) and 129 age- and sex-matched controls without CKD (65 males, 68<!--> <!-->±<!--> <!-->10<!--> <!-->years) who underwent 24-hour Holter monitoring. The proportion of successive normal sinus NN intervals that differ &gt;<!--> <!-->50<!--> <!-->ms (pNN50) and the high-frequency component (HF) were adopted as vagal parameters. The low- to high-frequency ratio (LF/HF ratio) was evaluated as a sympatho-vagal balance parameter. To evaluate the direct contribution of CKD and other comorbidities to the autonomic variation, the regression analysis was performed after we arbitrarily divided 24<!--> <!-->h into night-time (10<!--> <!-->PM–8<!--> <!-->AM) and day-time (8<!--> <!-->AM–10<!--> <!-->PM).</p></div><div><h3>Results</h3><p>The CKD patients had higher prevalence of hypertension, hyperuricemia, and low hemoglobin as compared to controls (P<!--> <!-->&lt;<!--> <!-->0.05). Both groups showed surges of pNN50 and HF nocturnally. However, these nocturnal surges were significantly suppressed in CKD (P<!--> <!-->&lt;<!--> <!-->0.05), reflecting the impaired vagal activity. Regression analysis demonstrated an independent relation between the nocturnal reduction of vagal parameters and CKD (P<!--> <!-->&lt;<!--> <!-->0.05), and also revealed that the LF/HF ratio was not related to CKD (P<!--> <!-->&gt;<!--> <!-->0.05), but to low Hb (P<!--> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusion</h3><p>The circadian autonomic, particularly vagal, fluctuations were impaired in non-diabetic CKD patients independently from aging and comorbidities. Further research is required to assess the association between this impairment and prognosis of CKD patients.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"9 ","pages":"Pages 22-27"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74967628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of diabetes mellitus on outcome of patients undergoing transcatheter aortic valve replacement","authors":"Sa'ar Minha,&nbsp;Marco A. Magalhaes,&nbsp;Israel M. Barbash,&nbsp;Itsik Ben-Dor,&nbsp;Ricardo O. Escarcega,&nbsp;Petros G. Okubagzi,&nbsp;Nevin C. Baker,&nbsp;Fang Chen,&nbsp;Rebecca Torguson,&nbsp;William O. Suddath,&nbsp;Lowell F. Satler,&nbsp;Augusto D. Pichard,&nbsp;Ron Waksman","doi":"10.1016/j.ijcme.2015.05.023","DOIUrl":"10.1016/j.ijcme.2015.05.023","url":null,"abstract":"<div><h3>Background</h3><p>The outcomes of patients with diabetes mellitus (DM) who are referred to surgical aortic valve replacement are poor in comparison to non-diabetic (ND) patients. However, the outcome of diabetic patients referred to transcatheter aortic valve replacement (TAVR) is less established. Further, DM and AS are both associated with left ventricular hypertrophy. It is not clear if alleviation of AS results in greater degree of reverse remodeling in DM patients in comparison to ND. We aim to evaluate if diabetes mellitus has an impact on TAVR outcome and remodeling patterns.</p></div><div><h3>Methods</h3><p>All consecutive patients who underwent TAVR (2007–2012) were included in this analysis. A comparison of baseline, procedural, post-procedural outcomes and echocardiographic left-ventricle mass indices was performed between DM and ND patients.</p></div><div><h3>Results</h3><p>DM was prevalent in 165 of 499 (33.0%) consecutive patients who underwent TAVR. DM patients were younger, weighed more, had higher rates of renal insufficiency and larger caliber peripheral vessels. Other than that, no disparities were noted in baseline characteristics. Procedural aspects were mostly similar between the groups but ND patients had higher rates of both vascular complications and bleeding. This did not translate into statistically significant differences in mortality both at 30<!--> <!-->days and at 1<!--> <!-->year (DM 6.7% vs. ND 10.5%; <em>p</em> <!-->=<!--> <!-->0.16 and DM 22.4% vs. 25.7%; <em>p</em> <!-->=<!--> <!-->0.48, respectively). Incidences of reverse remodeling patterns were similar between the two groups.</p></div><div><h3>Conclusion</h3><p>TAVR outcome is probably driven by baseline characteristics and post-operative complications while diabetes itself is not associated with poor outcome after TAVR.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"9 ","pages":"Pages 54-60"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.05.023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78709154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endostatin and osteopontin are elevated in patients with both coronary artery disease and aortic valve calcification","authors":"Michael Sponder ,&nbsp;Monika Fritzer-Szekeres ,&nbsp;Brigitte Litschauer ,&nbsp;Thomas Binder ,&nbsp;Jeanette Strametz-Juranek","doi":"10.1016/j.ijcme.2015.08.002","DOIUrl":"10.1016/j.ijcme.2015.08.002","url":null,"abstract":"<div><h3>Background</h3><p>The angiostatic factor endostatin (ES) plays an important role as mediator of angiogenesis. Elevated osteopontin (OPN) was associated with valve calcification in healthy individuals. The present study aimed to investigate ES and OPN levels in patients with both coronary artery disease (CAD) and aortic valve calcification (AVC).</p></div><div><h3>Methods and results</h3><p>In total 224 non- or ex-smoking patients (161 male, mean age: 61.09<!--> <!-->±<!--> <!-->11.02<!--> <!-->years; 63 female: mean age: 67.49<!--> <!-->±<!--> <!-->7.87<!--> <!-->years) with angiographically verified and quantified CAD were recruited. Serum ES and plasma OPN levels were measured by ELISA and AVC was evaluated by a parasternal short axis view and quantified as non-, mild or moderate/severe. There was a stepwise increase of ES measurable with increasing severity of AVC, independent from age, BMI and CAD-severity (p<!--> <!-->=<!--> <!-->0.018; F<!--> <!-->=<!--> <!-->4.09). OPN also increased significantly with the grade of AVC severity (p<!--> <!-->=<!--> <!-->0.029; F<!--> <!-->=<!--> <!-->3.61) but was no longer significant when the co-variables (p<!--> <!-->=<!--> <!-->0.31; F<!--> <!-->=<!--> <!-->1.18) were inserted.</p></div><div><h3>Conclusions</h3><p>This is the first study showing an association of ES with AVC in CAD-patients independent from age, BMI and CAD-severity which seems to be of distinct interest when trying to understand the process of heart valve calcification. OPN also correlates with AVC-severity but is mostly dependent on the age of the patients.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"9 ","pages":"Pages 5-9"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.08.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73788613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart failure: A difficult case of diagnostic definition","authors":"Francesca Mori,&nbsp;Massimo Piredda,&nbsp;Enrico Pusineri","doi":"10.1016/j.ijcme.2014.10.007","DOIUrl":"10.1016/j.ijcme.2014.10.007","url":null,"abstract":"<div><p>We describe the case of a 58<!--> <!-->year old man, who had recently undergone a coronary angioplasty with implantation of DES on the proximal circumflex branch and MO1 proximal for a NSTEMI, who had come to the emergency department complaining of severe pain in the back radiating in the precordial region. A few days later he developed a framework of acute heart failure with severe left ventricular dysfunction, accompanied by fever and blood cultures positive for <em>Staphylococcus aureus</em>. Instrumental examinations showed a massive coronary pseudoaneurysm originating from the circumflex branch ostium, which led to compressive action against anterior descending artery.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"9 ","pages":"Pages 28-30"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2014.10.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86848738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomics, a promising approach to translational research in cardiology","authors":"Martino Deidda ,&nbsp;Cristina Piras ,&nbsp;Pier Paolo Bassareo ,&nbsp;Christian Cadeddu Dessalvi ,&nbsp;Giuseppe Mercuro","doi":"10.1016/j.ijcme.2015.10.001","DOIUrl":"10.1016/j.ijcme.2015.10.001","url":null,"abstract":"<div><p>The metabolome is the complete set of metabolites found in a biological cell, tissue, organ or organism, representing the end products of cellular processes. Metabolomics is the systematic study of small-molecule metabolite profiles produced by specific cellular processes. mRNA gene expression data and proteomic analyses do not show the complexity of physiopathological processes that occur in a cell, tissue or organism. Metabolic profiling, in contrast, represents a paradigm shift in medical research from approaches that focus on a limited number of enzymatic reactions or single pathways, with the goal of capturing the complexity of metabolic networks.</p><p>In this article, we will provide a description of metabolomics in comparison with other, better known “omics” disciplines such as genomics and proteomics. In addition, we will review the current rationale for the implementation of metabolomics in cardiology, its basic methodology and the available data from human studies in this discipline. The topics covered will delineate the importance of being able to use the metabolomic information to understand the mechanisms of diseases from the perspective of systems biology, and as a non-invasive approach to the diagnosis, grading and treatment of cardiovascular diseases.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"9 ","pages":"Pages 31-38"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85492972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}